Cancers, Volume 15, Issue 10
2023 May-2 - 206 articles
Cover Story: The quest for more augmented and durable responses to melanoma immunotherapy has fueled recent efforts toward identifying novel immune checkpoint (IC) molecules that could be potentially targeted. The dynamic crosstalk between melanoma and immune effector cells is based on a complex network of many implicated IC molecules beyond PD-1 and CTLA-4, including LAG-3, TIGIT, TIM-3, VISTA, IDO1-2/TDO, CD27/70, CD39/73, HVEM/BTLA/CD160 and B7-H3. This paper explores all emerging IC molecules with emphasis on their co-inhibitory or co-stimulatory properties, with the aim of presenting all currently available clinical and preclinical data on their therapeutic potential. Understanding these IC-mediated pathways presents a unique opportunity to get a step closer to realizing “personalized immunotherapy”. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.